Etravirine: The renaissance of non-nucleoside reverse transcriptase inhibitors

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Background: Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations. Objective: To understand the unique features of etravirine and to evaluate its safety, efficacy and optimal use. Methods: The structure and the mechanism of action of etravirine in blocking the reverse transcriptase enzyme and the preclinical, pharmacokinetic and pharmacodynamic studies were reviewed. The DUET Phase III clinical trials and the resistance profile of etravirine were evaluated. Conclusions: Etravirine has unique activity against most HIV isolates that are resistant to other NNRTIs. Unlike other NNRTIs, it has a higher genetic barrier to developing high-grade resistance. In the DUET studies, etravirine demonstrated virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are important drug interactions that will need to be taken into consideration with its use.

Original languageEnglish (US)
Pages (from-to)3083-3094
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Issue number17
StatePublished - Dec 1 2008


  • AIDS
  • Etravirine
  • HIV
  • TMC 125

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Etravirine: The renaissance of non-nucleoside reverse transcriptase inhibitors'. Together they form a unique fingerprint.

Cite this